- Advanced search
- Immuno Portal
- Malaria Portal
Molecular properties generated using the CDK
|Compound class||Synthetic organic|
|PHT 427 | PHT427|
|PHT-427 is a novel dual inhibitor of 3-phosphoinositide dependent protein kinase 1 (PDK1) and Akt (protein kinase B) . The original identification of PHT-427 (compound 14) as an Akt inhibitor is described in  where it is shown to bind to the pleckstrin homology (PH) domain of Akt, not to the catalytic ATP binding site. PDK1 activates Akt by phosphorylating Thr308 in Akt's kinase domain.
The PDK1/Akt signaling pathway plays a key role in cancer cell growth, survival, and tumour angiogenesis and represents a promising target for oncology therapeutics [2,4].
|CAS Registry No.||1191951-57-1|
|GtoPdb PubChem SID||249565689|
|Search Google for chemical match using the InChIKey||BYWWNRBKPCPJMG-UHFFFAOYSA-N|
|Search Google for chemicals with the same backbone||BYWWNRBKPCPJMG|
|Search UniChem for chemical match using the InChIKey||BYWWNRBKPCPJMG-UHFFFAOYSA-N|
|Search UniChem for chemicals with the same backbone||BYWWNRBKPCPJMG|
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.✖
Cat. No. 4598